Otsuka Pharmaceutical Development & Commercialization, Inc.
Clinical trials sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., explained in plain language.
A subsidiary of Otsuka Holdings, focused on developing and commercializing pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug VIS171 enters human trials for lupus, hair loss, and kidney disease Results expected Oct 2026 (estimated)
- New schizophrenia pill shows promise in major trial Results expected Oct 2026 (estimated)
- New drug interaction study launches for repinatrabit Results expected Nov 2026 (estimated)
- Study aims to tailor PKU drug dosing for patients with organ impairment Results expected Feb 2027 (estimated)
- New shot could tame Sjögren's Flare-Ups Results expected Mar 2027 (estimated)
-
New drug VIS171 enters human trials for lupus, hair loss, and kidney disease
Disease control OngoingThis early-stage trial tests a new drug called VIS171 in 30 people with lupus, alopecia areata, or a kidney condition called FSGS. The main goal is to check safety and how the body handles the drug. Participants receive VIS171 as a shot under the skin, alongside their usual care,…
Phase 1 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New drug aims to slow kidney disease in IgA nephropathy patients
Disease control OngoingThis Phase 3 trial tested sibeprenlimab, a drug given as a shot under the skin, in 530 adults with IgA nephropathy, a kidney disease. The study compared the drug to a placebo to see if it could reduce protein in the urine and protect kidney function over time. Participants were a…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
New drug shows promise for slowing kidney disease in IgA nephropathy patients
Disease control By invitation onlyThis study looks at the long-term safety of a drug called sibeprenlimab for people with IgA nephropathy, a kidney disease. About 600 adults who completed earlier trials of this drug will continue receiving it for up to 2 more years. Researchers will track side effects and measure…
Phase 2/3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heart failure drug trial pulled before it even started
Disease control CancelledThis study was designed to test an experimental drug called OPC-131461 in people hospitalized for worsening heart failure who still had fluid buildup after standard treatment. The goal was to see if the drug could improve a key blood marker of heart strain over 30 days. However, …
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New shot could tame Sjögren's Flare-Ups
Disease control OngoingThis Phase 2 trial tests whether sibeprenlimab, a biologic drug given as a shot every 4 weeks, can reduce disease activity and symptoms in people with Sjögren's disease. About 83 adults with moderate-to-active disease will receive either the drug or a placebo, added to their usua…
Phase 2 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Kidney drug trial for newborns halted before it began
Disease control CancelledThis study aimed to see if the drug tolvaptan could help infants with a severe form of polycystic kidney disease (ARPKD) avoid needing dialysis or a kidney transplant in their first year of life. The trial was planned for babies between 28 days and 12 weeks old, but it was withdr…
Phase 3 • Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC